101results about How to "Prolong life" patented technology

The invention discloses a PROTACs compound for targeted degradation of PRMT5 and application of the PROTACs compound. The PROTACs compound comprises a compound as shown in the following formula, and related analogues or pharmaceutically acceptable salts, metabolites or prodrugs of the compound: in the # imgabs0 # formula, X represents a ligand bound to PRMT5 protein, Z represents a ligand of E3 ubiquitin ligase, and Y represents a linking group for linking X and Z; according to the invention, CRBN is used as E3 ligase, and a series of PRMT5-targeted PROTAC degradation compounds are designed and synthesized. The compound can effectively induce PRMT5 degradation, significantly inhibit proliferation, growth, migration, infiltration, clone formation and metastasis of tumor cells, promote apoptosis of cancer cells, promote autophagy of the tumor cells, prevent or overcome drug resistance of BTK inhibitors and / or prolong the lifetime of tumor patients, and has wide application prospects.

The present invention discloses a nano antibody against BCMA and its preparation method and application, and relates to the field of biomedical technology. The present invention uses CRISPR / Cas9 technology to knock out B2M and TRAC genes in T cells to prepare universal CAR-T cells; the nano antibody targeting BCMA and the natural ligand SIRPα extracellular N-terminal V region of CD47, the transmembrane region of CD28, the intracellular signal region of 4-1BB and the intracellular signal region of CD3ζ are connected in series to form a dual-targeted chimeric antigen receptor for the treatment of multiple myeloma, so as to solve the high recurrence problem faced by CAR-T cell therapy in the treatment of multiple myeloma. The universal CAR-T cells prepared by the present invention have strong killing activity against multiple myeloma cells, effectively improve the treatment effect, and provide a key material for the subsequent development of adoptive immunotherapy with high efficiency and lasting anti-tumor activity.

The utility model discloses a breathing machine humidifying tank and a breathing machine system, and relates to the field of medical instruments. The breathing machine humidifying tank comprises a tank body, a guide sleeve, a telescopic water bag and an operating rod. The tank main body is provided with a highest water line; the telescopic water bag is located in the tank body and horizontally arranged, the top of the telescopic water bag is higher than the highest water line, the telescopic water bag comprises a telescopic sleeve and a hard end plate, one end of the telescopic sleeve is connected with the tank body, the hard end plate is connected with the other end of the telescopic sleeve, and a water suction and drainage hole is formed in the hard end plate and lower than the highest water line. The guide sleeve and the telescopic water bag are arranged in the same direction, and the guide sleeve is connected with the tank body and corresponds to the telescopic water bag in position. And the operating rod penetrates through the guide sleeve, is matched with the guide sleeve and is sealed with the guide sleeve, and the operating rod is connected with the hard end plate. The breathing machine humidifying tank is installed on the breathing machine main machine, and a temperature and humidity sensor and a push-pull structure are arranged in a matched mode to obtain the breathing machine system. According to the utility model, the temperature and humidity of the humidified air at the patient end can be optimal.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GABA (gamma-aminobutyric acid) driven by lactobacillus rhamnosus to treatment of cerebral malaria of mice. According to the invention, the obviously enriched lactobacillus muricatum is found, and the lactobacillus muricatum is proved to be capable of generating GABA (gamma-aminobutyric acid). Afterwards, on the mouse cerebral malaria model, under the condition that the lactobacillus rhamnosus and the GABA are independently used or auxiliary dihydroartemisinin is used, the effect of the lactobacillus rhamnosus and the GABA on improving and treating the mouse cerebral malaria is evaluated. Results show that the strain and the metabolite GABA thereof can effectively improve behavioristics of mice and immune pathological injuries of all organs, reduce protozoemia and prolong the lifetime of the mice whether the strain is independently used or combined with dihydroartemisinin, and can effectively treat cerebral malaria of the mice compared with the strain which is independently used with drugs. The invention provides a brand-new solution for treating severe malaria, especially human brain malaria, caused by malignant malaria from the perspective that the probiotics drive metabolites of the probiotics to assist the anti-malarial drug in treating rat brain malaria.

The invention discloses application of PABPC3 as a marker for evaluating prognosis of metastatic ovarian cancer, and belongs to the technical field of biological diagnosis and medicine. Specifically, differential genes in an in-situ ovarian cancer and a metastatic ovarian cancer in a database are screened, and are combined with differential genes related to ovarian cancer prognosis in a pan-cancer database, so that a gene PABPC3 with remarkable differential expression is obtained. The influence of the gene PABPC3 on the activity, migration ability and the like of ovarian cancer cells is researched through cell experiments and in-vivo experiments, and the feasibility of the marker in evaluation of ovarian cancer prognosis is proved. Meanwhile, the invention also discovers that the expression of the knock-down gene PABPC3 can inhibit the metastasis of cancer cells. Therefore, the invention provides a novel strategy for detecting and treating ovarian cancer metastasis, which is expected to overcome the defects of the traditional detection and treatment mode, and provides a new choice for clinic.

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The invention relates to an oncolytic virus VSV-aPDL1 / aCD137 for expressing a bispecific antibody as well as a construction method and application of the oncolytic virus VSV-aPDL1 / aCD137. The preparation method comprises the following steps: firstly designing aPDL1 / aCD137, then synthesizing an aPDL1 / aCD137 gene in vitro, amplifying the aPDL1 / aCD137 gene, connecting the aPDL1 / aCD137 gene to a pT7-VSV whole genome plasmid to obtain a virus whole genome plasmid pT7-VSV-aPDL1 / aCD137, and then co-transfecting the plasmid and a helper plasmid to a 293T cell to obtain the VSV-aPDL1 / aCD137 oncolytic virus. According to the present invention, the local anti-tumor immune response of the tumor is activated through the virus, the infiltration of the lymphocyte to the tumor tissue is recruited, the anti-PD-L1 / anti-CD137 bispecific antibody is expressed, the inhibition of the PD-1 / PD-L1 pathway on the T cell is blocked, and the inhibition signal of the PD-1 / PD-L1 pathway on the tumor cell surface is reversed into the CD137 signal of the activated T cell, such that the functional failure of the T cell caused by the PD-1 / PD-L1 pathway can be blocked, and the anti-tumor immune response of the tumor can be inhibited; the function and viability of T cells can be further improved, long-term immune surveillance on tumors is realized, and long-acting anti-tumor immune response is generated. Experiments show that the oncolytic virus can significantly prolong the lifetime of tumor-bearing mice, and a new strategy is provided for development of solid tumor drugs.

The invention relates to the technical field of biological medicines, and provides a pharmaceutical composition for treating liver cancer, which is prepared from the following raw material medicines in parts by weight: 3 to 8 parts of radix paeoniae rubra, 1 to 3 parts of fructus sophorae, 3 to 10 parts of rhizoma polygoni cuspidati, 3 to 20 parts of spica prunellae, 3 to 20 parts of herba hedyotidis diffusae, 3 to 10 parts of herba violae, 2 to 5 parts of turtle shell, 1 to 5 parts of radix angelicae sinensis, 1 to 3 parts of rhizoma curcumae, 1 to 3 parts of apios fortunei maxim and 3 to 5 parts of fructus polygoni orientalis. According to the technical scheme, the problems that in the prior art, after radiotherapy and chemotherapy are conducted on patients, obvious side effects can be generated, such as the symptoms of inappetence, nausea and vomiting, diarrhea, stomachache, dental ulcer and the like, and some patients have the symptoms of listlessness, weakness, shortness of breath, alopecia and the like are solved.

The invention discloses a biomarker for predicting prognosis of an intrahepatic cholangiocarcinoma patient, a prediction model and application, and belongs to the field of biomedicine. According to the invention, single cell sequencing is carried out on matched intrahepatic cholangiocarcinoma and para-carcinoma tissues by using a BD Rhapsody platform, a tumor cell subset taking SPINK1 as a representative gene is screened out by using single cell sequencing data, and differential expression analysis is carried out on the subset and other epithelial cell subpopulations to obtain 249 differential genes. The differential genes are subjected to machine learning, a GBM model with the optimal prediction efficiency is selected, and a prediction model which contains 205 genes and is used for predicting the prognosis of the intrahepatic cholangiocarcinoma patient is established according to the GBM model. According to the prognosis prediction model, the prognosis prediction efficiency of the intrahepatic cholangiocarcinoma patient is improved, high-risk people can be more sensitively found, and key monitoring and more personalized treatment are carried out on the people, so that the death rate of the intrahepatic cholangiocarcinoma patient is reduced, and the lifetime of the patient is prolonged.

The invention relates to the technical field of prediction and evaluation of lung cancer samples, and discloses a prediction and evaluation method of a lung cancer sample, which comprises the following steps: collecting clinical information of a lung cancer patient, acquiring biological data of the lung cancer sample, sorting medical image data, extracting key genes, proteins or pathway characteristics from the biological data, important features related to the lung cancer are screened by using a statistical method or a machine learning algorithm, a proper machine learning or deep learning model is selected according to data characteristics and a prediction target, and the interpretability, stability and calculation complexity of the model are considered. According to the method, tumors with high-risk characteristics, such as tumors with high invasiveness and high metastasis potential, can be found and intervened in time through prediction and evaluation of lung cancer samples, so that the disease progress is delayed, the treatment effect is improved, the treatment effect and disease change can be monitored through regular prediction and evaluation of the lung cancer samples in the treatment process, and the treatment effect is improved. The treatment scheme is adjusted in time, and the maximization of the treatment effect is ensured.

The invention belongs to the technical field of biological medicines, and particularly relates to a gadolinium-based sulfonamide complex with a radiotherapy sensitization effect as well as preparation and application of the gadolinium-based sulfonamide complex. The preparation method comprises the following steps: dispersing sulfonamides and PVP in a mixed solution of ethanol and ethylene glycol, and stirring at room temperature to obtain a reaction solution A; dropwise adding Gd (NO3) 3.6 H2O into the reaction solution A, and continuously stirring to obtain a reaction solution B; and carrying out solvothermal reaction on the reaction solution B to obtain the gadolinium-based sulfonamide complex. The gadolinium-based sulfonamide complex prepared by the invention can increase the radiotherapy sensitivity by adjusting the tumor acidic microenvironment. Experiments prove that the gadolinium-based sulfonamide complex can effectively enhance the radiotherapy treatment effect, promote tumor cell apoptosis and slow down the tumor growth speed when being used in cooperation with radiotherapy.

The invention provides a nano material suitable for multi-mode diagnostic imaging and targeted photodynamic (PDT) and photo-thermal (PTT) cancer therapy, and belongs to the field of nano biomedicine. According to the invention, an upconversion material (NaYF4: Yb / Er / Gd) and a photo-thermal material (Bi2Se3) are taken as a core, mesoporous silica is taken as a shell, and a photosensitizer (Ce6) and lipid / PEG and acidity-triggered membrane (ATRAM) peptide coated on the surface of the shell are loaded. The PDT and PTT synergistic anticancer effect achieved through near-infrared laser induction is achieved, magnetic resonance imaging, thermal imaging and fluorescence imaging of tumors can be achieved, and the requirement for diagnosis and treatment integration is met. In addition, the in-vivo lifetime of the nano-carrier is effectively prolonged through lipid / PEG, and aggregation and premature degradation of the nano-carrier are prevented; and the pH-mediated acidity-triggered membrane peptide is utilized to improve the uptake of cancer cells to the nano-carrier, so that the effect of the nano-carrier and the cancer cells is enhanced.

The invention relates to the field of biological medicine, in particular to an Mmrn1 targeted inhibitor, an inhibition method and application. According to the application disclosed by the invention, firstly, the relationship between the expression of the MMRN1 gene in the acute myelogenous leukemia (AML) and the regulation and control of a'siglecan-siglecc 'axis is creatively disclosed. Therefore, the invention firstly provides a small interfering RNA (Ribonucleic Acid) targeting the Mmrn1 in the leukemia stem cell, and an application of the small interfering RNA in preparation of a'sialic acid glycan-siglecc 'axis immune checkpoint inhibitor.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine resistance. The pharmaceutical composition is prepared from active ingredients such as a radix sophorae flavescentis extract, a poria cocos extract, emodin, glucosamine, gambogic acid, tranilast and aspirin. The preparation method of the sophora flavescens extract and the poria cocos extract comprises the steps of raw material pretreatment, dynamic ultrasonic-microwave synergistic extraction, membrane separation and nanofiltration, high-efficiency countercurrent chromatography purification, vacuum low-temperature concentration, drying and the like. The pharmaceutical composition can be prepared into a plurality of pharmaceutical preparations such as tablets, capsules, granules, cream, injections and the like. The invention further provides a preparation method of the oral tablet for reversing pancreatic cancer gemcitabine drug resistance, and the pharmaceutical composition has a remarkable treatment effect on a drug resistance mechanism formed by up-regulating expression of SREBP1 by histone lactylation mediated PKM2 through an AKT / mTOR pathway. The pharmaceutical composition provided by the invention provides a new treatment choice for pancreatic cancer patients, and has an important clinical application value.

An electrolytic capacitor 1 includes: a capacitor element 3 in which an anode foil 5 and a cathode foil 7 each having a dielectric oxide film face each other across a separator 6; a body case 2 that houses the capacitor element 3; and a sealing member 4 that seals the body case 2. An electrolyte and a hydrophilic compound are held between the anode foil 5 and the cathode foil 7. A sealing member deterioration preventing agent immiscible with the hydrophilic compound is arranged inside the body case 2.

Provided are a steel material and a method for producing the same. The steel material exhibits excellent hydrogen embrittlement resistance in a high-pressure hydrogen gas environment and is, therefore, suitable for use in hydrogen storage tanks, hydrogen line pipes, and the like. A steel material for a high-pressure hydrogen gas environment has a predetermined chemical composition. The steel material has a tensile strength of 560 MPa or higher, and a fracture toughness value KIH exhibited by the steel material in a high-pressure hydrogen gas atmosphere is 40 MPa ·m1 / 2 or higher.

The invention relates to a method for in-vitro culture of BCG (Bacillus Calmette-Guerin) supernatant and adjuvant therapy of ovarian cancer, in particular to a method for preparing the in-vitro culture of BCG-Guerin supernatant and using the BCG-Guerin supernatant as an adjuvant therapy drug to be combined with a first-line platinum chemotherapeutic drug. The method comprises the following steps: firstly, culturing calmette-guerin bacteria in vitro, and collecting and purifying a culture supernatant product of the calmette-guerin bacteria to obtain the biological preparation with immunomodulatory activity. Then, according to the specific condition of the ovarian cancer patient, a personalized treatment scheme is formulated, the BCG in-vitro culture supernatant product is given to the patient in a proper mode, and meanwhile, the original platinum chemotherapy scheme is maintained. Clinical test results show that the method can significantly improve the curative effect of chemotherapy, reduce the side effect of chemotherapy, prolong the lifetime of a patient and improve the survival rate. The implementation of the invention provides a new and effective treatment means for ovarian cancer patients, and has wide clinical application prospects and profound social significance.

A control method and system for an electric power of a steam turbine generator of a nuclear power plant, the method comprises: S10, collecting a real-time thermal power of a first loop in a nuclear power plant; S20, on the basis of a moving average method, calculating a real-time moving thermal power of the real-time thermal power within a first set time; S30, performing front-end heat generation amount calculation processing on the real-time moving thermal power and the real-time thermal power, so as to obtain front-end actual heat generation amount; S40, performing a heat generation amount prediction operation according to a preset target average thermal power, the real-time moving thermal power and the front-end actual heat generation amount, so as to obtain a predicted heat generation amount; and S50, performing a conversion and efficiency correction operation on the base of the predicted heat generation amount, so as to obtain a given electric power value which is used for controlling an electric power of a steam turbine generator, and returning to S10.

A micro-inverter and a grid-tied output control method and device therefor. The micro-inverter comprises an inverter full-bridge circuit and an LC filter circuit. The LC filter circuit is grid-tied to a power grid by means of an output switch. The method comprises: acquiring a voltage amplitude, a frequency, and a phase of a power grid voltage by using phase locking; adjusting a power switching transistor driving an inverter full-bridge circuit to cause an output voltage of a micro-inverter to track the power grid voltage; and controlling the output switch to be turned off so that the micro-inverter works normally. According to the present application, before the output switch is turned off to grid-tie the micro-inverter, the power grid voltage is phase-locked and the output voltage of the micro-inverter is controlled to track the power grid voltage, so that damage to a power switching transistor caused by a current at the moment when the output switch is turned off can be effectively avoided, thereby effectively improving the reliability and the service life of the micro-inverter.

A composition for forming a colored layer includes a dye (A), an ionizing radiation-curable resin (B), a photoinitiator (C), and a solvent (D). The dye (A) contains a first colorant and a second colorant, the first colorant has a wavelength of maximum absorption in a range of 470 nm to 530 nm, and an absorption spectrum with a full width at half maximum of 15 nm to 45 nm, the second colorant has a wavelength of maximum absorption in a range of 560 nm to 620 nm, and an absorption spectrum with a full width at half maximum of 15 nm to 55 nm, and the ionizing radiation-curable resin (B) contains a resin having an amine structure.

The invention belongs to the field of medicines, discloses an application of a CSF1R inhibitor in preparation of a medicine for treating or relieving myelofibrosis, and also discloses a medicine for treating or relieving myelofibrosis. According to the application disclosed by the invention, a delta (5q) MDS mouse model constructed based on Diaph1- / -miR-146a- / -(DKO) is treated by giving a CSF1R inhibitor PLX3397, and the following positive effects are observed: PLX3397 can relieve anemia symptoms of a DKO mouse, remarkably reduce the number of peripheral blood and fibrocytes in the spleen of the DKO mouse, reduce deposition of reticular fibers and collagenous fibers in bone marrow and effectively improve myelofibrosis. In addition, PLX3397 can also reduce the clone formation ability of peripheral blood and spleen of the DKO mouse and prolong the lifetime of the DKO mouse. Flow cytometry analysis shows that PLX3397 treatment can increase the number of early erythroid progenitor cells and LSK cells in bone marrow of a DKO mouse, so that hematopoietic function defects of the DKO mouse are partially improved. Generally speaking, the invention reveals the potential curative effect of PLX3397 in treating MDS mouse disease models, and provides a new direction for treating and relieving myelofibrosis caused by clinical treatment of MDS.

An object of the present invention is to obtain a gas adsorbent, a gas adsorption sheet, a filter medium, and an air filter that are excellent in gas component adsorption capacity and excellent in long-term stability of the adsorption capacity and also re-release little odor after being used as an air filter. A main object of the present invention is to provide a gas adsorbent that contains an acid-impregnated activated carbon, a base-impregnated activated carbon, and an aldehyde adsorbent.

A liquid heating device 200 comprising: a container 100 having an internal space 100i and an inlet 103 and an outlet 105; and a ceramic heater171,172 of which a base-end portion 17R is retained by the container, the ceramic heater including ceramic sheet 17s which has a heat generation portion 17a and is wrapped around an outer circumference of a ceramic base 17g such that, at a wrap-meeting part of the ceramic sheet, a slit 17v extending in the axial-line L direction is formed as a non-heat generation portion, wherein the liquid is heated by the ceramic heater, the outlet is located apart from the inlet in the axial-line direction, and a first-axis n1 direction in a vicinity 105R of an opening end 105e facing the internal space, of the outlet, crosses the axial-line direction, and a front end of the heat generation portion is located on the base-end portion side relative to the outlet.

The invention discloses an extracellular vesicle for inducing monocyte differentiation as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The invention particularly discloses application of extracellular vesicles separated from M1 type macrophages in preparation of monocyte-derived macrophages, preparation of products for preparing the monocyte-derived macrophages or preparation of medicines for treating tumors in non-disease diagnosis and treatment. The extracellular vesicles separated from the M1 type macrophages can induce monocytes to be differentiated into anti-tumor macrophages through a TNF-alpha mediated pathway, have excellent blood-brain barrier penetrating power, can effectively reduce the tumor volume and prolong the lifetime, and are used for treating tumors such as glioma, and off-target toxicity is not observed.

The present invention pertains to a negative electrode for a lithium secondary battery, a method for manufacturing same, and a lithium secondary battery including same. More specifically, the negative electrode for a lithium secondary battery according to the present invention has a protective layer containing a three-dimensional structure composed of metal and lithium nitride, and thus uniform ionic conductivity and electrical conductivity can be induced on the surface of the negative electrode.

The invention belongs to the technical field of medicine. More specifically, the invention relates to application of telbivudine in preparation of drugs for preventing or treating breast cancer. The invention provides an application of telbivudine in preparation of a medicine for preventing or treating breast cancer. The invention proves that the telbivudine has an anti-breast cancer effect for the first time, and the telbivudine as the NSD2 inhibitor can effectively inhibit the growth of the breast cancer. Meanwhile, the telbivudine can remodel the immunosuppressive tumor microenvironment, reduce the infiltration of regulatory T cells (Treg), and significantly enhance the effector function of CD8 + T cells. More importantly, the telbivudine and the PD-1 antibody are combined to show a remarkable synergistic effect in a breast cancer mouse model, and the tumor inhibition effect and survival benefit are superior to those of a single drug. The combination scheme of the telbivudine and the PD-1 antibody significantly improves the sensitivity of breast cancer to immunotherapy, provides a new scheme for solving the problem of low clinical response rate of breast cancer immunotherapy, and has good application prospects and application values.

The invention discloses an ad hoc network dynamic topology routing optimization method and system based on a Deepseek lightweight large model, and the method specifically comprises the steps: collecting the information of each node in an ad hoc network, and standardizing the node information into a feature vector format which can be analyzed by the Deepseek model; the standardized node feature vectors are input into a Deepseek model, and the topological structure change trend in a short time in the future is predicted; generating a routing path selection strategy based on a topology change trend predicted by the model, testing in an ad hoc network simulation platform, and adjusting feature weight distribution of the model according to a test result; and deploying the adjusted strategy to an actual network, collecting routing performance data in real time as a new sample input model, iteratively updating the model, and improving the accuracy of topology prediction and routing optimization. According to the method, a response can be quickly made to a new network topology, the convergence speed is increased, accurate routing selection can be realized, node energy consumption is reduced, and the life cycle of the ad hoc network is prolonged.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The present invention relates to a coating composition which is an anticorrosive paint for ship structures and can be coated by a regular airless painting machine, and is solvent-free or contains a low solvent content. The coating composition according to an embodiment of the present invention may exhibit excellent pot life, atomization and drying time, and is eco-friendly due to having a high solid content and thus lower VOC emissions.